Latest news with #marketanalysis
Yahoo
2 days ago
- Business
- Yahoo
3 Global Dividend Stocks To Watch With Up To 4.8% Yield
Amidst a backdrop of muted market reactions to new U.S. tariffs and mixed economic signals from major global economies, investors are carefully navigating the current landscape. With the Nasdaq Composite showing resilience among U.S. indices and European markets buoyed by potential trade deals, dividend stocks remain a focal point for those seeking steady income in uncertain times. In this environment, strong dividend stocks can offer stability through reliable yields, making them an attractive option for investors looking to balance risk and reward in their portfolios. Top 10 Dividend Stocks Globally Name Dividend Yield Dividend Rating Yamato Kogyo (TSE:5444) 4.43% ★★★★★★ NCD (TSE:4783) 4.23% ★★★★★★ Japan Excellent (TSE:8987) 4.26% ★★★★★★ GakkyushaLtd (TSE:9769) 4.50% ★★★★★★ E J Holdings (TSE:2153) 4.80% ★★★★★★ DoshishaLtd (TSE:7483) 4.14% ★★★★★★ Daito Trust ConstructionLtd (TSE:1878) 4.43% ★★★★★★ CAC Holdings (TSE:4725) 5.00% ★★★★★★ Banque Cantonale Vaudoise (SWX:BCVN) 4.62% ★★★★★★ Allianz (XTRA:ALV) 4.46% ★★★★★★ Click here to see the full list of 1507 stocks from our Top Global Dividend Stocks screener. Here we highlight a subset of our preferred stocks from the screener. Consun Pharmaceutical Group Simply Wall St Dividend Rating: ★★★★☆☆ Overview: Consun Pharmaceutical Group Limited is engaged in the research, development, manufacturing, and sale of Chinese medicines and medical contrast medium products in the People's Republic of China with a market cap of HK$10.17 billion. Operations: Consun Pharmaceutical Group's revenue is primarily derived from the Consun Pharmaceutical Segment, contributing CN¥2.53 billion, and the Yulin Pharmaceutical Segment, adding CN¥442.84 million. Dividend Yield: 4.9% Consun Pharmaceutical Group's dividends are well-covered by earnings and cash flows, with payout ratios of 50.8% and 46.4%, respectively. However, past dividend payments have been volatile over the last decade, despite recent growth in earnings by 16.1%. The company trades at a good value relative to peers but offers a lower dividend yield compared to top-tier Hong Kong payers. Recent share buybacks may enhance shareholder value, while board changes could impact future strategic decisions. Dive into the specifics of Consun Pharmaceutical Group here with our thorough dividend report. Insights from our recent valuation report point to the potential undervaluation of Consun Pharmaceutical Group shares in the market. Ruentex Engineering & Construction Simply Wall St Dividend Rating: ★★★★☆☆ Overview: Ruentex Engineering & Construction Co., Ltd. operates in the construction industry and has a market cap of NT$47.25 billion. Operations: Ruentex Engineering & Construction Co., Ltd. generates revenue from three main segments: NT$2.16 billion from the Interior Decoration Design Segment, NT$4.70 billion from the Construction Materials Business Segment, and NT$20.65 billion from the Construction Division (excluding Interior Design Department). Dividend Yield: 4.1% Ruentex Engineering & Construction's dividends are covered by earnings and cash flows, with payout ratios of 68.1% and 45.6%, respectively, though past payments have been volatile. Despite a recent increase in dividend payments to TWD 7.7 per share, the yield remains lower than Taiwan's top-tier payers. The company trades significantly below its estimated fair value and has shown strong earnings growth, with Q1 net income rising to TWD 549.43 million from TWD 395.87 million last year. Navigate through the intricacies of Ruentex Engineering & Construction with our comprehensive dividend report here. According our valuation report, there's an indication that Ruentex Engineering & Construction's share price might be on the cheaper side. Advanced Power Electronics Simply Wall St Dividend Rating: ★★★★☆☆ Overview: Advanced Power Electronics Co., Ltd. operates in Taiwan, offering power discrete products and has a market cap of NT$9.65 billion. Operations: Advanced Power Electronics Co., Ltd. generates revenue of NT$3.04 billion from its Electronic Components & Parts segment. Dividend Yield: 3.7% Advanced Power Electronics' dividends are well-covered by earnings and cash flows, with payout ratios of 58.1% and 41.3%, respectively. Despite a history of volatility, dividends have grown over the past decade but remain unreliable. The dividend yield of 3.74% is below Taiwan's top-tier payers, though the company trades at a favorable price-to-earnings ratio of 15.6x compared to the market average. Recent earnings showed significant growth, with Q1 net income reaching TWD 171.55 million from TWD 86.35 million last year. Get an in-depth perspective on Advanced Power Electronics' performance by reading our dividend report here. In light of our recent valuation report, it seems possible that Advanced Power Electronics is trading beyond its estimated value. Taking Advantage Explore the 1507 names from our Top Global Dividend Stocks screener here. Got skin in the game with these stocks? Elevate how you manage them by using Simply Wall St's portfolio, where intuitive tools await to help optimize your investment outcomes. Invest smarter with the free Simply Wall St app providing detailed insights into every stock market around the globe. Contemplating Other Strategies? Explore high-performing small cap companies that haven't yet garnered significant analyst attention. Fuel your portfolio with companies showing strong growth potential, backed by optimistic outlooks both from analysts and management. Find companies with promising cash flow potential yet trading below their fair value. This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned. Companies discussed in this article include SEHK:1681 TWSE:2597 and TWSE:8261. This article was originally published by Simply Wall St. Have feedback on this article? Concerned about the content? with us directly. Alternatively, email editorial-team@ Error while retrieving data Sign in to access your portfolio Error while retrieving data Error while retrieving data Error while retrieving data Error while retrieving data
Daily Mail
3 days ago
- Business
- Daily Mail
EXCLUSIVE Housing market CONTRACTS in dramatic new signal of crisis... one Southern city is at the epicenter
Frustrated home sellers are pulling their homes off the market because they can't get the prices they want. A softer housing market saw delistings surge 47 percent across the country in May compared to the same time last year.
Yahoo
3 days ago
- Business
- Yahoo
Netflix Produces Strong Q2 FCF, But NFLX Stock Dips - Is It a Buy Here?
Netflix, Inc. (NFLX) reported yesterday that its Q2 revenue grew +15.9% and its FCF grew 14.2% Y/Y, but dipped on a Q/Q basis. NFLX stock could be a bargain, given its 20.4% FCF margin, and using a 1.65% FCF yield. Shorting out-of-the-money (OTM) put options works as well. NFLX is at $1,212.77 in midday trading, down over 4.8% today, but it could be a buying opportunity. This article will show why. More News from Barchart Insider Trading Alert: Here's Who Bought Nvidia and AMD Stock Before the U.S. Chip Deal with China AMZN Trade Idea: Capture Gains Without Chasing the Stock 3 Unusually Active Cash-Secured Puts in Quality Companies for Attractive Income Get exclusive insights with the FREE Barchart Brief newsletter. Subscribe now for quick, incisive midday market analysis you won't find anywhere else. Last quarter, after the company released its results, I projected in an April 20 Barchart article that NFLX stock could be worth $1,176 per share. Today, I am raising that target price by +14% to $1,383 per share using a similar method as before. Strong FCF Margins The table below, taken from Netflix's Q2 shareholder letter, shows that although revenue rose 15.9% Q/Q, Netflix's operating cash flow and free cash flow (FCF) dipped in Q2. Moreover, the quarterly FCF margin (i.e., FCF / revenue) fell from 25.2% to 20.4%. Don't focus on that. Over the past 12 months, its FCF margins have stayed very strong. shows the trailing 12-month (TTM) FCF margins on its cash flow analysis tab. For example, last quarter the TTM FCF margin was 18.54%, so it has risen almost 200 basis points this quarter to 20.5%. As a result, we can use that to forecast Netflix's margins going forward. After all, management raised its revenue forecast and indicated its operating margins would stay stable. Forecasting FCF Analysts now project 2025 revenue of $44.84 billion and 2026 revenue of $50.37 billion. That means the next 12-month (NTM) revenue forecast is $47.6 billion (up from $46.96 billion in my prior Barchart article estimate). So, if we assume that Netflix will continue to make a 20.4% FCF margin over the next year: $47.6b x 0.204 = $9.71 billion FCF NTM estimate We can use this to value NFLX stock over the next 12 months. How? Price Targets for NFLX Stock One way is to use its TTM FCF yield. That metric assumes that 100% of its FCF will be paid out to shareholders and the stock will have a 'yield.' shows that Netflix generated $8.5 billion in FCF over the trailing 12 months (this can also be computed from the Netflix quarterly FCF figures above). Since NFLX's market capitalization today is $515.356 billion, according to Yahoo! Finance, its TTM FCF yield is: $8.5b / $515.356 b = 0.0165 = 1.65% That is the same as a multiple of 60.6x (i.e., the reciprocal of 1.65%). Therefore, we can multiply our NTM FCF forecast by 60.5: $9.71b x 60.5 = $587.46 billion NTM market cap That result is +14% higher than today's $515.4 billion market cap. As a result, our price target is 14% higher than today's price: $1,212.77 x 1.14 = $1,382.56 p/sh price target So, assuming Netflix maintains a 20.4% FCF margin over the next year, NFLX stock could potentially be worth 14% more or $1,383 per share. This assumes the market values its FCF at over 60x, or a 1.65% FCF yield. There is no guarantee this will occur. For example, the multiple could fall (i.e., the FCF yield might rise). As a result, it makes sense to set a lower buy-in price. One way to do this, and get paid, is to sell short out-of-the-money (OTM) put options in nearby expiry periods. Shorting OTM Puts For example, look at the Aug. 22 expiry period, just over one month from now. It shows that the $1,165.00 put option strike price, which is over 4% lower than today's trading price, has an attractive premium worth shorting. The $1,165.00 put has a midpoint price of $19.68, which allows an investor who enters an order to 'Sell to Open' this put contract to make an immediate yield of 1.69% (i.e., $19.68/$1,165 = 0.0189). This also means that the potential breakeven buy-in price is $1,165.00 - $19.68, or $1,145.32 (i.e., if NFLX falls to $1,165.00 on or before Aug. 22). That is still over 5.5% lower than today's price. So, it provides good downside protection and a potential lower buy-in price. Moreover, investors willing to take on more risk can sell short the $1,170 strike price put. The account would receive $20.98 (i.e., $2,098 per put contract) on a secured collateral of $117,000 (i.e., $1,170 x 100 shares per put contract). That provides an immediate yield of 1.793% (i.e., $20.98/$1,170), and the investor has a breakeven price (if NFLX falls to $1,170) of $1,149.02, or -5.4% below today's price. Moreover, an investor in this strike price stands to potentially make an upside of +20%, if NFLX hits our target price: $1382.56/$1149.02 = 1.203 -1 = +20.3% upside In addition, even if NFLX stock doesn't fall to this breakeven price, an investor has an expected return (ER)of over 5% over 3 months. This can be done by using a mix of these two short put trades (i.e., (1.69% +1.793%)/2 = 1.7415%) over 3 months: 1.7415% x 3 = 5.22% 3 mo ER The bottom line is that investors in NFLX puts using this method can set a lower buy-in price and potentially make a good expected return. However, investors in puts should be careful to understand all the risks associated with this type of trade. One way to do this is to study Barchart's Learn Center tabs on options trading. On the date of publication, Mark R. Hake, CFA did not have (either directly or indirectly) positions in any of the securities mentioned in this article. All information and data in this article is solely for informational purposes. This article was originally published on
Yahoo
4 days ago
- Business
- Yahoo
Nontuberculous Mycobacteria (NTM) Opportunity Assessment and Forecast to 2033 Featuring Janssen, Novartis, Meiji Seika Pharma, Insmed, Daiichi Sankyo, MannKind, Paratek, Nobelpharma, GSK, Pfizer
Comprehensive analysis of the NTM therapeutics market: Overview of disease, epidemiology, treatment options, and forecast from 2023-2033 for 7 major markets. Insights include pipeline trends, market drivers, competitive landscape, and strategies for growth and investment in the NTM market. Dublin, July 17, 2025 (GLOBE NEWSWIRE) -- The "Nontuberculous Mycobacteria (NTM): Opportunity Assessment and Forecast" report has been added to report provides an assessment of the NTM therapeutics market including disease overview, epidemiology, current treatment options, unmet needs and opportunities, R&D strategies, pipeline assessment, and market refers to infection with a group of bacteria within the Mycobacterium genus, which excludes Mycobacterium tuberculosis (tuberculosis) and Mycobacterium leprae (leprosy). NTM infections are noncontagious, opportunistic infections that cause a wide range of clinical disease in patients with pre-existing health conditions or compromised immune systems.). In terms of global burden, NTM lung disease is relatively uncommon. It is suggested that host defense mechanisms in most healthy individuals are sufficient to prevent or suppress NTM infection. Patients who develop NTM lung disease likely have susceptibility factors such as pre-existing comorbidities that make them vulnerable to these Highlights Report deliverables include a Pdf report and an Excel-based forecast model Forecast includes the 7 major markets (7MM) Forecast covers the period 2023-2033 Scope Overview of NTM, including classification, epidemiology, diagnostic and treatment paradigms. Annualized NTM therapeutics market revenue, cost of therapy per patient, and treatment usage patterns forecast from 2023 to 2033. Key topics covered include assessment of marketed therapies and pipeline agents, unmet needs, pipeline assessment and market outlook for the US, 5EU, and Japan over the 10-year forecast period. Pipeline analysis: Emerging novel trends under development, and detailed analysis of late-stage pipeline drugs. Analysis of the current and future market competition in the 7MM NTM therapeutics market. Insightful review of the key industry drivers and barriers. Reasons to Buy Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies, and by identifying the companies with the most robust pipelines. Develop business strategies by understanding the trends shaping and driving the 7MM NTM therapeutics market. Drive revenues by understanding the key trends, innovative products and technologies, market segments, and companies likely to impact the NTM therapeutics market in the future. Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors. Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage. Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments and strategic partnerships. Key Topics Covered: 1. Preface1.1. Contents1.2. Abbreviations1.3. Related Reports2. Executive Summary3. Disease Overview3.1. Overview of NTM3.2. NTM Market SWOT Analysis3.3. Classification of NTM3.4. NTM Risk Factors4. Epidemiology4.1. Diagnosed Incident Cases NTM, N, Both Sexes, 2023-334.2. Diagnosed Prevalent Cases of NTM, Both Sexes, N, 2023-334.3. Diagnosed Incident Cases of NTM, PNTM, and DNTM, Both Sexes, N, 20234.4. Diagnosed Prevalent Cases of NTM, PNTM, and DNTM, Both Sexes, N, 20234.5. Sources and Methodology for Diagnosed Incident Cases of NTM, PNTM, and DNTM4.6. Sources and Methodology for Diagnosed Prevalent Cases of NTM, PNTM and DNTM4.7. Sources and Methodology for Diagnosed Incident and Prevalent Cases of NTM4.8. Sources and Methodology for Diagnosed Incident and Prevalent Cases of PNTM4.9. Sources and Methodology for Diagnosed Incident and Prevalent Cases of DNTM5. Current Treatment Options5.1. PNTM Diagnostic Paradigm5.2. Treatment Paradigm5.3. Current Treatment Options6. Unmet Needs and Opportunities6.1. Unmet Needs in NTM6.2. New Therapeutic Options with Improved Efficacy6.3. Improved Diagnostic Methods6.4. Improved Clinical Trials7. R&D Strategies7.1. Trends in Clinical Trial Design in NTM7.2. Trends in Deal-Making in NTM8. Pipeline Assessment8.1. NTM Pipeline Overview8.2. Late-Stage Pipeline Products for NTM8.3. NTM Clinical Trials (Phase II/III) Overview9. Market Outlook9.1. NTM Market Forecast9.2. PNTM Market Forecast9.3. DNTM Market Forecast9.4. Market Drivers and Barriers10. Appendix Competitive Landscape Janssen Novartis AG Meiji Seika Pharma Co Ltd Insmed Inc Daiichi Sankyo Co Ltd MannKind Corp Paratek Pharmaecuticals Inc Nobelpharma Co Ltd GlaxoSmithKline AG Pfizer For more information about this report visit About is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends. CONTACT: CONTACT: Laura Wood,Senior Press Manager press@ For E.S.T Office Hours Call 1-917-300-0470 For U.S./ CAN Toll Free Call 1-800-526-8630 For GMT Office Hours Call +353-1-416-8900Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
4 days ago
- Business
- Yahoo
JPMorgan's Jamie Dimon: Fed independence is 'absolutely critical'
Big Bank earnings are underway with JPMorgan (JPM) and Wells Fargo (WFC) releasing results. Yahoo Finance Executive Editor Brian Sozzi joins Morning Brief to share his takeaways from the earnings so far, including comments from Jamie Dimon about the Federal Reserve's independence as President Trump criticizes the central bank for not cutting rates. To watch more expert insights and analysis on the latest market action, check out more Morning Brief here. Let's drill a little deeper now on those bank earnings. Executive editor, Brian Sozzi, has been listening into those earnings calls. He's joining now from the Yahoo Finance newsroom. So, what are some of your takeaways, Sozzi? Yeah, Julie. I got three different headphones plugged into through my different ears so I can listen to Wells Fargo, all these companies, uh, BlackRock, too. But look, uh, the JP Morgan, uh, conference call is the one I'm listening to right on Yahoo Finance. Great new function on our site. I encourage everyone to check it out. Really enjoy listening to it on there. Um, nothing real in terms of fireworks from this JPMorgan or Morgan earnings call. See in the stock, uh, reverse some of those early losses after the print or the earnings beat this morning. Now in the green here in the pre-market, where the real fireworks, Julie, came in the reporter call which JPMorgan always has about a half an hour before the analyst call. Uh, Jamie Diamond saying this is starting to make news already. He vice, he views, uh, the Fed independence as quote absolutely critical, uh, and then also quote, it's important for the Fed to be independent. So, uh, Diamond voicing support for an independent Federal Reserve and of course, that's in contrast to everything we've heard of the Trump administration in the past months, that is, uh, one that is continuing to attack Fed chairman Jerome Powell, wants the lower interest rates. Jamie Diamond saying it's important for the institution to be independent. Uh, that's my real head takeaway so far, uh, here, Julie, on JPMorgan. Yeah, really interesting, um, and as we know, he is always outspoken. Anything else from the other banks that you, that you want to highlight, Sozzi? Yeah, just how bad a quarter Wells Fargo was. Three months ago, uh, we were sitting here, uh, not us, because I didn't buy into any Wells Fargo turnaround, uh, but they were promoting, uh, the bank is starting to turn around, where they start returning to capital to shareholders. This quarter really reversed all of that. You compare to how Wells Fargo did in markets, investment banking, trading, you name it, whatever it is, they badly underperformed JPMorgan and I suspect when Bank of America reports, they will, uh, they will show better results than a Wells Fargo. And I know they're not direct comparisons, Wells Fargo and BlackRock, but BlackRock is calling out this morning record, uh, assets under management of 12.53 trillion, a positive metric for them completely opposite to what we've heard, uh, from Wells Fargo today, in addition, of course, cutting their outlook for the full year in terms of net profits.
